Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.72 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | DGKA | P23743 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446024 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL5437712 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL95546 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL5438831 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL5448496 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL5440882 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL4077569 | 1.00 | NAAA (0.72) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL2537171 | 0.98 | NAAA (0.68) | NAAARAD52NPSR1DGKAFAAH | |
| SCHEMBL473880 | 0.91 | — | — | |
| SCHEMBL3984068 | 0.84 | NAAA (0.69) | NAAARAD52NPSR1DGKAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0185079-B1 | N-SUBSTITUTED BUTYRAMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1988-10-19 | — | — | EP | claimed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| EP-0119954-B1 | 3-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE | CIBA-GEIGY AG (CH) | 1990-03-14 | — | — | EP | disclosed |
| EP-0185079-B1 | N-SUBSTITUTED BUTYRAMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | NAAA 4355/4885RAD52 3868/4885NPSR1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.